Abstract
Surgical treatment is curative only at an early stage of renal cell carcinoma (RCC). However, due to late diagnosis, most of the patients present with metastases or develop metastatic disease after nephrectomy. Accordingly, five year survival rate is very low. Chemotherapy or radiation are not useful for treatment of RCC. There have been numerous clinical trials on systemic immunomodulative therapies. The response rate was low due to severe dose limiting side effects (1). In order to increase the local concentration of cytotoxic drugs or cytokines without enhancing systemic toxicity one may use monoclonal antibodies as a carrier system capable of targeting tumor cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Abbreviations
- γGT:
-
gamma glutamyltransferase
- Cam θ:
-
calicheamicin θ
- mAb:
-
monoclonal antibody
- RCC:
-
renal cell carcinoma
References
Goey SH, Verweij J, Stoter G., 1996: Immunotherapy of metastatic renal cell cancer. Ann.Onc. 7, 887–900
Fischer P, Störkel S, Haase W, Scherberich JE., 1991: Differential diagnosis of histogenetically distinct human epithelial renal tumours with a monoclonal antibody against gamma-glutamyltransferase. Cancer Immunol Immunother 33, 382–8
Fischer P, Scherberich JE, Schoeppe W., 1990: Comparative biochemical and immunological studies on gamma-glutamyltransferases from human kidney and renal cell carcinoma applying monoclonal antibodies. Clin Chim Acta 191, 185–200
Thoenes W, Störkel S, Rumpelt HJ., 1986: Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181, 125–43
Kaufmann O, Dietel M, Scherberich JE, Gaedicke G, Fischer P., 1997: Immunohistochemical differentiation of metastases of renal carcinomas versus other carcinomas with anti-GGT monoclonal antibody 138H11. Histopathology 31, 31–37
Fischer P, Baum RP, Tauber M, Boeckmann W, Weier S, Scherberich JE., 1992: Immunoscintigraphic localization of renal tumours in an extracorporeal perfusion model with a monoclonal antibody against gamma-glutamyltransferase. Cancer Immunol Immunother 35, 283–8
Reisfeld R, Mueller B, Schrappe M, Wargalla U, Yang H, Wrasidlo W., 1991: Antibody-drug conjugates for cancer therapy. Immunol Allergy Clin N Amer 11, 341–58
Nicolaou KC, Dai WM, Tsay SC, Estevez VA, Wrasidlo W. 1992: Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity. Science 256, 1172–8
Nicolaou KC, Li T, Nakada M, Hummel C, Hiatt A, Wrasidlo W. 1994: Calicheamicin θ: A rationally designed caliceamicin with extremely potent and selective DNA cleaving properties and apoptosis inducing activity. Angew Chem Int Ed 106, 183–186
Chapman AE, Goldstein LJ., 1995: Multiple drug resistance: Biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol 22, 17–28
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Schmidt, C.S., Wrasidlo, W., Kaufmann, O., Scherberich, J.E., Gaedicke, G., Fischer, P. (1998). Monoclonal Antibody 138H11 against Gamma-Glutamyltransferase Provides a Possible Tool for Targeting Calicheamicin θ to Renal Cell Carcinomas. In: Walden, P., Trefzer, U., Sterry, W., Farzaneh, F., Zambon, P. (eds) Gene Therapy of Cancer. Advances in Experimental Medicine and Biology, vol 451. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5357-1_66
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5357-1_66
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7444-2
Online ISBN: 978-1-4615-5357-1
eBook Packages: Springer Book Archive